Orchard Therapeutics PLC (ORTX)
Stock Price:
$5.31 USD
-0.38 (-6.68%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
515.89M |
| Revenue (ttm) |
2.51M |
| Net Income (ttm) |
n/a |
| Shares Out |
97.26M |
| EPS (ttm) |
-1.91 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$5.31 |
| Previous Close |
$5.69 |
| Change ($) |
-0.38 |
| Change (%) |
-6.68% |
| Day's Open |
5.69 |
| Day's Range |
5.24 - 5.72 |
| Day's Volume |
460,601 |
| 52-Week Range |
5.10 - 17.48 |
More Stats
| Market Cap |
515.89M |
| Enterprise Value |
296.25M |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
97.26M |
| Float |
65.00M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-1.91 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.14M |
| Short Ratio |
6.73 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
205.29 |
| PB Ratio |
1.92 |
| Revenue |
2.51M |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
219.64M |
| Net Cash / Share |
2.26 |
| Gross Margin |
67.97% |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-34.14% |
| ROE |
-66.39% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
7 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.00*
(276.65% upside)
Low
13.0
Current: 5.31
High
29.0
Target: 20.00
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 2.51 | 2.08 | - | - |
| Revenue Growth | 21.05% | - | - | - |
| Gross Profit | 1.71 | 1.65 | - | - |
| Operating Income | -173 | -235 | -38.51 | -19.20 |
| Net Income | -163 | -230 | -39.74 | -19.09 |
| Shares Outstanding | 93.24 | 22.56 | 8.87 | 7.10 |
| Earnings Per Share | -1.75 | -10.22 | -4.48 | -2.69 |
| Operating Cash Flow | -166 | -97.54 | -32.49 | -14.57 |
| Capital Expenditures | -4.37 | -4.03 | -1.56 | -0.19 |
| Free Cash Flow | -170 | -102 | -34.05 | -14.76 |
| Cash & Equivalents | 329 | 336 | 89.86 | 3.50 |
| Total Debt | 45.91 | - | - | 1.40 |
| Net Cash / Debt | 283 | 336 | 89.86 | 2.10 |
| Assets | 399 | 366 | 97.29 | 4.28 |
| Liabilities | 100 | 54.70 | 10.89 | 3.84 |
| Book Value | 299 | 311 | 86.41 | -16.52 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Orchard Therapeutics PLC |
| Country |
United Kingdom |
| Employees |
252 |
| CEO |
Bobby Gaspar |
Stock Information
| Ticker Symbol |
ORTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ORTX |
| IPO Date |
October 31, 2018 |
Description
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type MPS-IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is based in London, the United Kingdom.